LSNE Successfully Completes MHRA Inspection - - BioPharm International

ADVERTISEMENT

LSNE Successfully Completes MHRA Inspection



The CMO Lyophilization Services of New England (LSNE) reports that its manufacturing facility in Bedford, New Hampshire has received a Certificate of GMP Compliance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture asepticlyophilized drug products for use in the European Union. LSNE underwent an initial inspection in May 2013 and was found to be compliant with EU GMP, with no critical or major findings. After completion of an audit and registration, LSNE was issued a certificate ofGMP compliance of a Pharmaceutical Manufacturer from the MHRA. The Bedford facility is now certified for the manufacture of sterile lyophilized drug products to be marketed in the EU.

Source: LSNE

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here